Morgan Stanley raised the firm’s price target on Bath & Body Works to $49 from $48 and keeps an Overweight rating on the shares. The firm leaves the Q3 report, in which Bath & Body “unexpectedly” delivered topline upside on core product strength and subsequently raised fiscal year guidance, with “incremental conviction” in the company’s ability to deliver at least low-single digit percentage steady-state growth over time, the analyst tells investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBWI:
- Bath & Body Works price target raised to $38 from $32 at Wells Fargo
- Bath & Body Works price target raised to $52 from $51 at Deutsche Bank
- Bath & Body Works price target raised to $34 from $28 at Barclays
- Bath & Body Works Exceeds Q3 Expectations, Raises Guidance
- Macy’s uncovers employee fraud, Summit to be acquired: Morning Buzz